Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLL3xB7-H3 bsADC + DLL3xSEZ6 bsADC
- Development stage
- Preclinical
- Lead developer
- Biocytogen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DLL3xB7-H3 bsADC + DLL3xSEZ6 bsADC is a combination of two bispecific antibody-drug conjugates (bsADCs) designed for enhanced targeting in small-cell lung cancer (SCLC) and other solid tumors. The DLL3xB7-H3 bsADC targets Delta-like ligand 3 (DLL3) and B7-H3, while the DLL3xSEZ6 bsADC targets DLL3 and Seizure 6 antigen (SEZ6); both leverage bispecific antibody formats to bind multiple tumor-associated antigens overexpressed in SCLC, enabling improved internalization, payload delivery, and potent cytotoxicity via their conjugated payloads. Developed by Biocytogen, this preclinical combination demonstrates superior anti-tumor activity in SCLC models compared to monospecific ADCs by addressing tumor heterogeneity and antigen escape.[4][6]
02
Targets
SEZ6B7-H3DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on DLL3xB7-H3 bsADC + DLL3xSEZ6 bsADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLL3xB7-H3 bsADC + DLL3xSEZ6 bsADC.